SWTX - SpringWorks Therapeutics - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US85205L1070
Cancer, Tumor, Inhibitors, Therapies, Medicines, Treatments
SpringWorks Therapeutics Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative medicines for underserved patient populations suffering from rare diseases and cancer.
The company's lead product candidate, OGSIVEO (nirogacestat), is an oral small molecule gamma secretase inhibitor currently in Phase III DeFi trial for the treatment of desmoid tumors, a rare and debilitating condition. Additionally, nirogacestat is being developed as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer, and is currently in Phase 2 clinical development.
SpringWorks Therapeutics is also advancing mirdametinib, an oral small molecule MEK inhibitor, which is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a genetic disorder that causes tumors to grow on nerve tissue. Furthermore, the company is exploring mirdametinib in combination with lifirafenib in a Phase 1b clinical trial for patients with advanced or refractory solid tumors, as well as in monotherapy and combination approaches to treat other genetically defined solid tumors, including low-grade gliomas in pediatric and young adult patients.
In addition to its pipeline of small molecule inhibitors, SpringWorks Therapeutics is developing Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which are commonly found in various types of cancer.
The company has established strategic collaborations with leading biopharmaceutical companies, including BeiGene, Ltd. and GlaxoSmithKline LLC, as well as license agreements with Pfizer Inc. for nirogacestat and mirdametinib. Additionally, SpringWorks Therapeutics has partnerships with academic institutions, such as Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology, and Dana-Farber Cancer Institute, to access novel small molecule inhibitors of the TEA Domain and Epidermal Growth Factor Receptor, respectively.
Founded in 2017, SpringWorks Therapeutics is headquartered in Stamford, Connecticut, and is committed to improving the lives of patients with rare diseases and cancer. For more information, please visit https://www.springworkstx.com.
Drawdown (Underwater) Chart
SWTX Stock Overview
Market Cap in USD | 2,254m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 1987-06-05 |
SWTX Stock Ratings
Growth 5y | 6.19 |
Fundamental | -57.8 |
Dividend | |
Rel. Performance vs Sector | -1.43 |
Analysts | 4.50/5 |
Fair Price Momentum | 26.47 USD |
Fair Price DCF | - |
SWTX Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
SWTX Growth Ratios
Growth Correlation 3m | -73.6% |
Growth Correlation 12m | -8.1% |
Growth Correlation 5y | -29.5% |
CAGR 5y | 9.36% |
CAGR/Mean DD 5y | 0.22 |
Sharpe Ratio 12m | 0.69 |
Alpha vs SP500 12m | 3.55 |
Beta vs SP500 5y weekly | 0.66 |
ValueRay RSI | 22.17 |
Volatility GJR Garch 1y | 48.03% |
Price / SMA 50 | -14.18% |
Price / SMA 200 | -26.76% |
Current Volume | 476.2k |
Average Volume 20d | 906.3k |
External Links for SWTX Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 29.89 with a total of 476,219 shares traded.
Over the past week, the price has changed by -1.97%, over one month by -7.40%, over three months by -18.78% and over the past year by +30.52%.
According to ValueRays Forecast Model, SWTX SpringWorks Therapeutics will be worth about 29.1 in October 2025. The stock is currently trading at 29.89. This means that the stock has a potential downside of -2.71%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 67.5 | 126 |
Analysts Target Price | 50.2 | 67.8 |
ValueRay Target Price | 29.1 | -2.71 |